Propanc Biopharma Publishes Pilot Study Showing Anti-Tumor Activity for PRP Combo
Propanc Biopharma, Inc. (PPCB) released results from a pilot study published in Scientific Reports evaluating its PRP proenzyme combination. The preclinical research demonstrated that the fixed-ratio 1:6 PRP formulation inhibited key tumor drivers and reduced tumor growth in orthotopic pancreatic and ovarian cancer models. In addition, observational findings indicated encouraging survival signals in advanced cancer patients while maintaining a non-cytotoxic and favorable tolerability profile.
The findings highlight PRP's ability to target metastasis pathways, including angiogenesis, cellular invasion, and epithelial-mesenchymal transition. By demonstrating efficacy in orthotopic models—which closely mirror human disease compared to standard xenografts—the study helps validate the biological mechanism behind the treatment. However, despite the published findings, shares of Propanc Biopharma fell 6.25% to $0.4125 in recent trading.
While the pilot study offers early evidence of anti-tumor activity and patient survival potential, the clinical data remains preliminary and non-controlled. Investors will be monitoring whether the company moves forward with formal, controlled clinical trials to confirm both safety and therapeutic efficacy in larger patient populations.
Key points
- A pilot study published in Scientific Reports showed Propanc Biopharma's PRP combo reduced tumor growth in pancreatic and ovarian models.
- The 1:6 PRP formulation inhibited key metastasis pathways including angiogenesis, cell invasion, and epithelial-mesenchymal transition.
- Observational data revealed encouraging survival signals in advanced patients alongside a favorable, non-cytotoxic safety profile.
- Propanc Biopharma shares fell 6.25% to $0.4125 following the news.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What did Propanc Biopharma's pilot study show about PRP?
The study published in Scientific Reports showed that Propanc's PRP proenzyme combination reduced tumor growth in pancreatic and ovarian cancer models and exhibited encouraging survival signals in advanced patients.
How did Propanc Biopharma stock react to the PRP study results?
Propanc Biopharma (PPCB) stock declined 6.25% to $0.4125 following the release of the pilot study data.
What is the next step for Propanc Biopharma's PRP treatment?
Because the current findings come from preclinical models and observational data, formal controlled clinical trials will be needed to confirm efficacy and safety in humans.